Breaking

Who owns ‘brain rot’?: inside the international legal drama over a beloved meme The 27+ best deals on home essentials to stock up on for fall Prime Day King Charles and Elton John in the audience for Apple music workshop Exclusive: Promising Brain Cancer Vaccine Gives Hope to Patients SpaceX alumni nab $100M to rethink shipping with autonomous freight trains ‘I reside in Monaco’: billionaire said to have quit UK over potential wealth tax had already left X expands its ‘Gametime’ sports hub beyond the NFL, starting with MLB All aboard the Tuchel train? England camp has clear winners and losers Eckert’s Spygate ban may be lenient, but no sane manager will try the same trick again Man Utd and Liverpool eye Truffert - Thursday's gossip

NEWSREEL

The day, in 30-second reels.

--:--:--

Tech / Reel

Tech · Video brief

Trump administration proposes a rule it says could save Medicare patients $1.1 billion on drugs

A proposed rule by the Trump administration could save Medicare patients $1.1 billion on drugs by changing how hospitals apply discounts. While patients may benefit with up to $800 in annual savings, hospitals, especially those in low-incom...

AP News· Jul 2, 2026 · 1:54 PM · 35 views

Video won't play? Watch on YouTube →

A proposed rule by the Trump administration could save Medicare patients $1.1 billion on drugs by changing how hospitals apply discounts. While patients may benefit with up to $800 in annual savings, hospitals, especially those in low-income areas, might face financial challenges. How will this impact the 340B program and the future of drug pricing? #Medicare #Healthcare #DrugPrices #TrumpAdministration #340BProgram

Originally reported by AP News. Read the full story →

More in Tech

Who owns ‘brain rot’?: inside the international legal drama over a beloved meme

The Guardian· 48 minutes ago

Robot data startup Mecka AI nabs $60M from Sequoia

TechCrunch· 48 minutes ago

Meta’s Oversight Board has a warning for AI companies building their own watchdogs

NBC News· 13 hours ago

0 Comments

No comments yet. Be the first.